(PrEP) against HIV infection is largely safe, effective,1 2 3 4 and cost effective,4 5 6 7 NHS England has declined to make it available on the NHS, arguing that HIV prevention is the responsibility of local government.8NHS England's apparent appetite for legalistic cost shunting,9 and ...
An HIV prevention drug will finally be made available in England after the NHS announced plans for a three-year trial of the treatment it had initially resisted in the courts. Pre-exposure prophylaxis (PrEP) will be made available to 10,000 people at high risk of HIV infection, with sexual...
为解决英格兰黑人女性在HIV暴露前预防(PrEP)获取中存在严重健康不平等问题,研究人员通过定性研究结合行为改变理论(COM-B模型),联合黑人女性群体、医疗专业人员(HCPs)及混合组开展焦点小组(FG)和协同设计工作坊。研究发现知识缺口、制度性种族主义等六大障碍,并开发出以社区为主导的多模式PrEP宣传运动干预方案。该研究为消...
理由是根据两项HIV检测窗口期研究的结果,在没有PEP/PrEP的情况下实验室第4代检测窗口期的中位数为暴露后18天(IQR 13-24),窗口期的第99位百分数为44.3天[2][3],因此许多国际上著名的卫生组织使用45天作为实验室第4代检测排除HIV感染的时间,例如美国CDC、英国HIV协会(BHIVA)、加拿大安大略省公共卫生部、澳大利亚...
The cost-effectiveness of PrEP is likely to be dependent on theses variables, NICE said. Truvada’s list price is £355.73 for 30 tablets, but the drug is offered at a confidential discount to the NHS for HIV prevention. Truvada was approved by EU regulators for HIV PrEP in August....
Kevin Fenton, Director of Health and Wellbeing at Public Health England commented: “We’re delighted to be working in partnership with NHS England on this major new addition to the national HIV prevention programme. This comes after much planning and preparation to ensure we can successfully coor...
按需服用保护有效率86%。具体数据可以去看CDC官网：https://www.cdc.gov/hiv/risk/estimates/prevention...
doi:10.1136/bmj.i4347BMJBmjGarethIacobucci
HIV is a serious virus which, if left untreated, affects your immune system. PrEP is suitable for people who are at risk of getting infected. It can be taken daily (for all kinds of sex), or in the days before and after sex (for only anal sex, not vaginal or frontal sex). It ...
NHS Scotland accepts PrEP for HIV preventionNo Abstract available for this article.doi:10.1007/s40274-017-3938-3NoneSpringer International PublishingPharmacoeconomics & Outcomes News